The results of the phase III CHAARTED trial investigating androgen deprivation therapy (ADT) plus docetaxel for men with metastatic hormone-sensitive prostate cancer challenge the long-established standard of care of ADT alone for these men. The next step will be to integrate these results into clinical practice.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502–1512 (2004).
Petrylak, D. P. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351, 1513–1520 (2004).
Sweeney C. et al. Impact on overall survival with chemohormonal therapy for hormone sensitive newly metastatic prostate cancer: An ECOG-led phase 3 randomized trial [abstract]. J. Clin. Oncol. 32 (Suppl. 5), LBA2 (2014).
Sweeney, C. J. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 373, 737–746 (2015).
Gravis, G. et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomized, open-label, phase 3 trial. Lancet Oncol. 14, 149–158 (2013).
James, N. D. et al. Docetaxel and/or zoledronic acid for hormone naïve prostate cancer: First overall survival results from STAMPEDE [abstract]. J. Clin. Oncol. 33 (Suppl.), 5001 (2015).
American Society of Clinical Oncology. ASCO.org [online]
Hussain, M. et al. Intermittent versus continuous androgen deprivation in prostate cancer. N. Engl. J. Med. 368, 1314–1325 (2013).
Fizazi, K. et al. Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. Ann. Oncol. 26, 1660–1667 (2015).
Hussain M. et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J. Clin. Oncol. 24, 3984–3990 (2006).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Higano, C. Mapping the course after CHAARTED. Nat Rev Urol 12, 656–658 (2015). https://doi.org/10.1038/nrurol.2015.255
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2015.255
